Currently, there are 209.12M common shares owned by the public and among those 153.14M shares have been available to trade.
The company’s stock has a 5-day price change of 11.22% and 31.64% over the past three months. GENI shares are trading 9.06% year to date (YTD), with the 12-month market performance down to -10.37% lower. It has a 12-month low price of $4.62 and touched a high of $8.45 over the same period. GENI has an average intraday trading volume of 1.81 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 20.23%, 24.31%, and 17.96% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Genius Sports Limited (NYSE: GENI) shares accounts for 64.15% of the company’s 209.12M shares outstanding.
It has a market capitalization of $1.42B and a beta (3y monthly) value of 1.97. The earnings-per-share (ttm) stands at -$0.39. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.14% over the week and 4.26% over the month.
Earnings per share for the fiscal year are expected to increase by 57.25%, and 89.32% over the next financial year.
Looking at the support for the GENI, a number of firms have released research notes about the stock. Citigroup stated their Buy rating for the stock in a research note on June 13, 2024, with the firm’s price target at $9. Goldman coverage for the Genius Sports Limited (GENI) stock in a research note released on April 16, 2024 offered a Buy rating with a price target of $7.50. B. Riley Securities was of a view on April 05, 2024 that the stock is Buy, while Macquarie gave the stock Outperform rating on December 21, 2023, issuing a price target of $11. Cantor Fitzgerald on their part issued Overweight rating on October 12, 2023.
